Page last updated: 2024-12-07

n(6)-(delta(2)-isopentenyl)adenine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N(6)-dimethylallyladenine : A 6-isopentenylaminopurine in which has the isopentenyl double bond is located between the 2 and 3 positions of the isopentenyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID92180
CHEMBL ID476189
CHEBI ID17660
SCHEMBL ID459276
MeSH IDM0041696

Synonyms (102)

Synonym
6-(.gamma.,.gamma.-dimethylallylamino)purine
n-(.delta.2-isopentenyl)adenine
n-(3-methyl-2-butenyl)adenine
6-[(3-methyl-2-butenyl)amino]purine
nsc-106958
n6-(3-methyl-2-butenyl)adenine
1h-purin-6-amine, n-(3-methyl-2-butenyl)-
n6-(.delta.2-isopentenyl)adenine
n6-(2-isopentenyl)adenine
n-(.gamma.,.gamma.-dimethylallyl)adenine
n6-(.delta.2-isopentenyl)aminopurine
adenine, n-(3-methyl-2-butenyl)-
n6-(2-isopentenyl)-adenine
AC-15608
isopentenyl adenine
n-(3-methylbut-2-en-1-yl)-7h-purin-6-amine
n(6)-(delta2-isopentenyl)adenine
CHEBI:17660 ,
NSC106958 ,
6-(3-methyl-2-buten-1-ylamino)purine
isopentenyladenine
n6-isopentenyladenine
n(6)-dimethylallyladenine
(3-methyl-but-2-enyl)-(7(9)h-purin-6-yl)-amine
n6-(delta2-isopentenyl)adenine
TIMTEC1_003281
n-(3-methyl-2-butenyl)-9h-purin-6-amine
OPREA1_344117
n-(3-methylbut-2-en-1-yl)-9h-purin-6-amine ,
NCGC00014084
2ip ,
C04083
n6-dimethylallyladenine
n6-(delta2-isopentenyl)-adenine
6-(gamma,gamma-dimethylallylamino)purine
n6-(3-methylbut-2-enyl)adenine
2365-40-4
6-(gamma,gamma-dimethylallylamino)purine, bioreagent, plant cell culture tested, >=90%
6-(gamma,gamma-dimethylallylamino)purine, bioreagent, plant cell culture tested, 1 mg/ml
6-(gamma,gamma-dimethylallylamino)purine, bioreagent, plant cell culture tested, >=98.5%
NCI106958
n-(delta2-isopentenyl)adenine
6-((3-methyl-2-butenyl)amino)purine
n6-(delta2-isopentenyl)aminopurine
n(6)-(delta(2)-isopentenyl)adenine
n-(gamma,gamma-dimethylallyl)adenine
n-(3-methyl-2-butenyl)-1h-purin-6-amine
nsc 106958
ipade
NCI60_000165
NCISTRUC2_000921
NCISTRUC1_000935
NCGC00097193-01
2EXM
D-4760
6-(3,3-dimethylallylamino)purine
n6-delta2-isopentenyladenine
HMS1543F03
DB08768
BRD-K62158429-001-01-7
CHEMBL476189
n-(3-methylbut-2-enyl)-7h-purin-6-amine
AKOS005257639
(3-methylbut-2-enyl)purin-6-ylamine
n-(3-methylbut-2-enyl)-9h-purin-6-amine
n6-(2-isopentenyl)-adenine;6-(gamma,gamma-dimethylallylamino)purine
A816825
unii-v500bb256z
v500bb256z ,
CCG-38046
NCGC00014084-02
FT-0629731
AKOS015914857
S5690
6-[(3-methylbut-2-en-1-yl)amino]purine
SCHEMBL459276
n6-.delta.2-isopentenyl)adenine
n-6-(3,3-dimethylallyl)adenine
n(6)-(.delta.2-isopentenyl)aminopurine
n-(3-methyl-2-butenyl)-1h-purin-6-amine #
9h-purin-6-amine, n-(3-methyl-2-buten-1-yl)-
6-n-(3-methylbut-2-enylamino)purine
bryokinin
enadenine
6-isopentenyladenine
n-isopentenyladenine
AC-32452
DTXSID10178325
3-methylbut-2-enyl(7h-purin-6-yl)amine
6-(gamma,gamma-dimethylallylamino)purine, vetec(tm) reagent grade, >=98.5%
Q569031
mfcd00132998
AS-17517
HY-112103
6-(|a,|a-dimethylallylamino)purine
CS-0043352
n6-(delta 2-isopentenyl) adenine
HMS3886C18
n6-(2-lsopentenyl)adenine
n-6-( delta 2-isopentenyl)-adenine
6-(,-dimethylallylamino)purine
6-(y,y-dimethylallylamino)purine

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
"The use of the aqueous extracts of Eleutherococcus senticosus in combination with either cytarabine or N6-(delta 2-isopentenyl)-adenosine gave additive antiproliferative effects against L1210 murine leukemia."( Cytotoxic effects of Eleutherococcus senticosus aqueous extracts in combination with N6-(delta 2-isopentenyl)-adenosine and 1-beta-D-arabinofuranosylcytosine against L1210 leukemia cells.
Hacker, B; Medon, PJ, 1984
)
0.27

Bioavailability

ExcerptReferenceRelevance
"Cell membrane permeability is an important determinant for oral absorption and bioavailability of a drug molecule."( Highly predictive and interpretable models for PAMPA permeability.
Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
cytokininA phytohormone that promote cell division, or cytokinesis, in plant roots and shoots.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
6-isopentenylaminopurine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (10)

PathwayProteinsCompounds
Regulation of leaf development1722
Cytokinins Degradation113
trans-zeatin biosynthesis718
cytokinins 7-N-glucoside biosynthesis014
cytokinins 9-N-glucoside biosynthesis015
cytokinins degradation114
cytokinin-O-glucosides biosynthesis614
Gravitropism under normal or artificial gravity environments5811
Regulation of lemma joints development and leaf angle by cytokinin111
cytokinins degradation519
cytokinins 7-N-glucoside biosynthesis219
cytokinins 9-N-glucoside biosynthesis217
trans-zeatin biosynthesis721
cytokinin-O-glucosides biosynthesis615
Responses to stimuli: abiotic stimuli and stresses9526
Trans-zeatin biosynthesis022
Cytokinins conjugates biosynthesis08
Cytokinins 9-N-glucoside biosynthesis014

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Cell division protein kinase 2Homo sapiens (human)Ki78.000078.000078.000078.0000AID977610
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytokinin dehydrogenase 1Zea maysKm1.80001.80003.65005.5000AID416147
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID1224817Assays to identify small molecules inhibitory for eIF4E expression2015Chemistry & biology, Jul-23, Volume: 22, Issue:7
Internal Ribosome Entry Site-Based Bicistronic In Situ Reporter Assays for Discovery of Transcription-Targeted Lead Compounds.
AID1645848NCATS Kinetic Aqueous Solubility Profiling2019Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
AID1508591NCATS Rat Liver Microsome Stability Profiling2020Scientific reports, 11-26, Volume: 10, Issue:1
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
AID1508612NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Highly predictive and interpretable models for PAMPA permeability.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1811Experimentally measured binding affinity data derived from PDB1995Proteins, Aug, Volume: 22, Issue:4
Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB1995Proteins, Aug, Volume: 22, Issue:4
Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine.
AID416147Activity at Zea mays CKX1 expressed in Pichinia pastoris assessed as aldehyde production by 4-aminophenol assay2009Bioorganic & medicinal chemistry, Mar-01, Volume: 17, Issue:5
Synthesis, characterization and biological activity of ring-substituted 6-benzylamino-9-tetrahydropyran-2-yl and 9-tetrahydrofuran-2-ylpurine derivatives.
AID1293509Antiviral activity against Enterovirus 71 infected in human RD cells assessed as cell viability after 3 days by MTS assay2016European journal of medicinal chemistry, Mar-23, Volume: 111Modification of the length and structure of the linker of N(6)-benzyladenosine modulates its selective antiviral activity against enterovirus 71.
AID1293511Selectivity index, ratio of CC50 for human RD cells to EC50 for Enterovirus 712016European journal of medicinal chemistry, Mar-23, Volume: 111Modification of the length and structure of the linker of N(6)-benzyladenosine modulates its selective antiviral activity against enterovirus 71.
AID416148Ratio Kcat to Km for Zea mays CKX1 receptor2009Bioorganic & medicinal chemistry, Mar-01, Volume: 17, Issue:5
Synthesis, characterization and biological activity of ring-substituted 6-benzylamino-9-tetrahydropyran-2-yl and 9-tetrahydrofuran-2-ylpurine derivatives.
AID1293510Cytotoxicity against human RD cells2016European journal of medicinal chemistry, Mar-23, Volume: 111Modification of the length and structure of the linker of N(6)-benzyladenosine modulates its selective antiviral activity against enterovirus 71.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (85)

TimeframeStudies, This Drug (%)All Drugs %
pre-199015 (17.65)18.7374
1990's15 (17.65)18.2507
2000's23 (27.06)29.6817
2010's28 (32.94)24.3611
2020's4 (4.71)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.20

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.20 (24.57)
Research Supply Index4.45 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.20)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (4.71%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other81 (95.29%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]